Nagihan UĞURLU, Fatma YÜLEK, Şule Berk ERGUN, Mehmet Doğan AŞIK, Semra IŞIKOĞLU, Emine AKÇAY

Investigation of oxidative and antioxidative status in patients with diabetic cataracts

To investigate the oxidative and antioxidative status in diabetic patients with cataracts and nondiabetic patients with cataracts as compared to controls. Materials and methods: There were 149 subjects included in the present study. Blood was collected from type 2 diabetic patients suffering from cataracts (diabetic cataract; n = 42), senile nondiabetic patients suffering from cataracts (nondiabetic cataracts; n = 60), and healthy subjects of a control group (n = 47). Serum levels of total oxidant status (TOS), total antioxidant status (TAS), total thiol levels (TTLs), and paraoxonase 1 (PON1) were investigated in the samples. Results: TTLs were significantly reduced in diabetic cataract patients (444.8 µmol/L) compared with both nondiabetic cataract patients (525.1 µmol/L) and the control group (569.9 µmol/L). Plasma PON1 levels also were significantly reduced in diabetic cataract patients (241.9 U/L) relative to the control group (178.3 U/L). There were no statistically significant differences between TAS and TOS levels among groups. Conclusion: The present study demonstrates a significant reduction in serum TTLs and serum PON1 activities in diabetic cataract patients compared with controls. These findings represent a failure in the antioxidant system, which may be related to the cataractogenic process.

Anahtar Kelimeler:

Key words: Oxidative status, antioxidative status, diabetic cataract

Investigation of oxidative and antioxidative status in patients with diabetic cataracts

Keywords:

Key words: Oxidative status, antioxidative status, diabetic cataract,

PDF

___

Truscott RJ. Age related nuclear cataract-oxidation is the key. Exp Eye Res 2005; 80: 709–25.
Fletcher AE. Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and agerelated macular degeneration. Ophthalmic Res 2010; 44: 191–
Gul A, Rahman MA, Hasnain SN, Salim A, Simjee SU. Could oxidative stress associate with age products in cataractogenesis? Curr Eye Res 2008; 33: 669–75.
Pollreisz A, Schmidt-Erfurth U. Diabetic cataract -pathogenesis, epidemiology and treatment. J Ophthalmol 2010; 2010: 608751.
Bron AJ, Sparrow J, Brown NA, Harding JJ, Blakytny R. The lens in diabetes. Eye 1993; 7: 260–75.
Klein BEK, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology 1985; 92: 1191–6.
Nielsen NV, Vinding T. The prevalence of cataract in insulin dependent and non-insulin dependent-diabetes mellitus. Acta Ophthalmol 1984; 62: 595–602.
Yildirim Z, Yildirim F, Ucgun NI, Kilic N. The evaluation of the oxidative stress parameters in nondiabetic and diabetic senile cataract patients. Biol Trace Elem Res 2009; 128: 135–43.
Gul A, Rahman MA, Salim A, Simjee SU. Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. Age (Dordr) 2008; 30: 303–9.
Crabbe MJ. Cataract as a conformational disease - the Maillard reaction, alpha-crystallin and chemotherapy. Cell Mol Biol 1998; 44: 1047–50.
Ahmed N. Advanced glycation end products role in pathology of diabetic complications. Diab Res Clin Pract 2005; 67: 3–21.
Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23–30.
Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J 1995; 9: 1173–82.
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 157–
Halliwell B, Gutteride JMC. Free Radicals in Biology and Medicine. 4th ed. Oxford: Oxford University Press; 2006.
Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical formation. Exp Eye Res 1999; 68: 457–64.
Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277–85.
Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103–11.
Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001; 54: 176–86.
Ucakhan OO, Karel F, Kanpolat A, Devrim E, Durak I. Superoxide dismutase activity in the lens capsule of patients with pseudoexfoliation syndrome and cataract. J Cataract Refract Surg 2006; 32: 618–22.
Donma O, Yorulmaz E, Pekel H, Suyugül N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr Eye Res 2002; 25: 9–
Wlodek L. Beneficial and harmful effects of thiols. Pol J Pharmacol 2002; 54: 215–23.
Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112–9.
Coral K, Raman R, Rathi S, Rajesh M, Sulochana KN, Angayarkanni N, Paul PG, Ramakrishnan S. Plasma homocysteine and total thiol content in patients with exudative age related macular degeneration. Eye 2006; 20: 203–7.
Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009; 410: 1–12.
Efrat M, Aviram M. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. Adv Exp Med Biol 2010; 660: 153–66.
Hashim Z, Ilyas A, Saleem A, Salim A, Zarina S. Expression and activity of paraoxonase 1 in human cataractous lens tissue. Free Radic Biol Med 2009; 46: 1089–95.
Hashim Z, Zarina S. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin Biochem 2007; 40: 705–9.
Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase / arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126–38
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70–7.
Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hydrochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257–62.
Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000; 36: 1 –30.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405–12.
Sayın O, Arslan N, Altun ZS, Akdoğan G. In vitro effect of resveratrol against oxidative injury of human coronary artery endothelial cells. Turk J Med Sci 2011; 41: 211–8.
Demircioğlu Rİ, Usta B, Sert H, Muslu M, Gözdemir M. Taurine is protective against oxidative stress during cold ischemia in the rat kidney. Turk J Med Sci 2011; 41: 843–9.
Aydos OS, Avcı A, Özkan T, Karadağ A, Gürleyik E, Altınok B. Antiproliferative, apoptotic and antioxidant activities of wheatgrass (Triticum aestivum L.) extract on CML (K562) cell line. Turk J Med Sci 2011; 41: 657–63.
Bor Z, Arslan R, Bektaş N, Pırıldar S, Dönmez AA. Antinociceptive, antiinflammatory, and antioxidant activities of the ethanol extract of Crataegus orientalis leaves. Turk J Med Sci 2012; 42: 315–24.
Andersson A, Isaksson A, Brattsom L. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem 1999; 45: 1084–6.
Maxwell SR. Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol Suppl 2000; 95: 65–71.
Blum A, Lupovitch S, Khazim K, Peleg A, Gumanovsky M, Yeganeh S, Jawabreh S. Homocysteine levels in patients with risk factors for atherosclerosis. Clin Cardiol 2001; 24: 463–6.
Cavalca V, Cighetti G, Bamonti F, Loaldi A, Bortone L, Novembrino C, De Franceschi M, Belardinelli R, Guazzi MD. Oxidative stress and homocysteine in coronary artery disease. Clin Chem 2001; 47: 887–92
Başkol G, Seçkin KD, Bayram F, Tanrıverdi F. Investigation of serum paraoxonase-1 activity and lipid levels in patients with hyperthyroidism. Turk J Med Sci 2012; 42: 1166–71.
Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229–35.
Quéméneur T, Martin-Nizard F, Kandoussi A, Kyndt X, Vanhille P, Hachulla E, Hatron PY, Fruchart JC, Duriez P, Lambert M. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin Arthritis Rheum 2007; 37: 149–55.
Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082–8.
Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E, Saraymen R, Ustdal M. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006; 220: 12–6.
Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K . Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 2001; 50: 657–60.
Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, Masiá R, Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003; 88: 5422–6. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochemical Pharmacology 1998; 55: 1747–58.
Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T, Payette H, Khalil A . Age-related decrease in highdensity lipoproteins antioxidant activity is due to an alteration in the PON1’s free sulfhydryl groups. Atherosclerosis 2006; 185: 191–200.